Camallergy

United Kingdom
Newdigate, England, United Kingdom, W2 1AS

Company profile

Camallergy company profile

Camallergy (Cambridge Allergy Ltd) is a biopharmaceutical company dedicated to providing innovative, patient-centric treatments to address the millions of patients suffering worldwide from food allergies. Camallergy’s lead product is a novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The Company’s unique intellectual property and treatment regimen are based on the clinical work initiated at Cambridge University Hospitals NHS Foundation Trust in Cambridge, UK.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2015-12-07

Headquarters

Postal code
W2 1AS
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
7
Total equity funding
$3.5M
Last funding
Equity Crowdfunding / $264,495 / 2023-12-11
Last equity funding
Equity Crowdfunding / $264,495
Investors
3
Lead investors
2
Founders
3
Articles
4

Founders and investors

Founders

Andrew ClarkPamela EwanSherden Timmins

Lead investors

Innovate UKJonathan Milne

Investors

CrowdcubeInnovate UKJonathan Milne